.svg)
Better Robotics. Better Implants. Better Knee Replacements.
We're changing the way orthopedic surgery is done. Our system combines personalized knee implants with precision robotic surgical assistants, giving patients a better-fitting knee replacement with minimally invasive surgery. 100,000 knee replacements failing each year in a $19.4B market, represents an enormous opportunity for us.
Share Price
NASDAQ Here We Come. Meet MGRM.
We’ve reserved the Monogram stock ticker - MGRM - a key step in our journey to going public*. In the meantime, our current private round remains open.
How Our Technology Makes Knee Replacements Better Than Ever
By combining implants optimized for each patient with robotically precise surgery, our patients will have a more stable knee replacement done with fewer incisions.
Download Investor Presentation & Company Updates
The First Surgical Robot of Its Kind
Surgery is an incredibly invasive stressful process. Our surgical robots precisely create a digital map of a patient and make as minimal incisions as possible alongside surgeons to create a better surgery experience.
In fact, this year we held a live demonstration where a Monogram robot successfully operated on a cadaver alongside a surgeon in front of a virtual audience of over 5,000 people.
What makes the Monogram robot so effective?
- 7 degrees of freedom to boost range of motion
- Closed loop tracking
- Active navigated milling gently clears space for the implant
The World Deserves Personalized Implants
You wouldn’t buy a shoe if you were between sizes or it didn’t fit quite right. So why would you accept generic-sized knee implants? Patients have been forced to compromise with poor fitting implants for decades. We fixed it. Our implants are patient-optimized and designed to meet individual patient’s anatomy as closely as possible. The result is a decrease in micro-mobility which increases the likelihood of acceptance of the implant by a patient.
Watch our LIVE Demo
We put our revolutionary robotic technology to the test. Watch us perform a LIVE knee replacement on a cadaver in front of thousands of viewers.
Our Solution Is Needed. 100,000 Knee Replacements Fail Each Year.
The result of our system is a better-fitting knee replacement. Our surgical robots create highly accurate bone cavities for our custom implants. Because of this level of precision, our implants don’t use brittle bone cement, a relic of the past that is still used in 92% of knee replacements.
A Broken Industry
Joint replacement technology is mostly the same today as it was 40 years ago. Surgeons use crude instruments like hand saws and jigs to prepare the bone for rigid, generic implants. No wonder the results are so bad.
- Over 100,000 knee replacements fail each year
- Up to 20% of patients have chronic pain after an implant surgery
- Instability, malalignment, and failure of fixation cause 50% of early revision surgeries
The Knee Replacement Market is $19.4B
By 2027, 50% of all knee replacements will be robotic. We aim to have the first active navigated robotic arm on the market. If we are able to succeed we will capture a fraction of this massive market
Company Highlights
Generated Revenue
NSF Grant
Cadaver Lab
20 Patents
$38M
First
Company
We’re Planning to List on the NASDAQ as MGRM
This is an especially exciting time to invest in Monogram because we intend to list our stock on the NASDAQ this year. This is a rare opportunity to own shares in a company before it’s planned to trade on an exchange. And once we’re on the exchange our shares will be eligible to be bought by ETFs, mutual funds, institutional investors, and be covered by investment banks
Download Investor Presentation & Company Updates
What People are Saying
.png){kind=logo}
"Given the sheer number of knee and hip replacement procedures every year, the fact that joint reconstruction technology has remained unchanged for over 50 years is perplexing."
.jpeg){kind=logo}
"Monogram has a first-to-market advantage in a sector that's about to get even more competitive."
"Monogram Orthopedics is ushering in personalized orthopedic care by combining proprietary 3D printing technology with next-generation navigated surgical robotics".
"Monogram is developing a better way by commercializing highly personalized joint implants unique to every patient and a first-of-its-kind active robotics system that performs precise bone cuts."
"Monogram has conducted studies with UCLA and demonstrated Monogram process was about seven times more stable than current hip replacement techniques."
Meet the Team
Douglas Unis, Md
Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.
Benjamin Sexson - CEO
Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.
Noel Knape
Mr. Knape has over 25 years of experience leading financial departments in multinational, publicly-traded companies. He holds a Master of International Management from the American Graduate School of International Management.
Kamran Shamaei, PhD
Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots.
Christopher Scifert, PhD
Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.
Kevin Posey
Muhammad Afnan
Sophia Sangiorgio, PhD
Laura Gilmour
Matt DiCicco, M.S.
Dr. Roshan Shah
Robert Jamieson
Dr. Matthew E. Heinrich
Darwin Chen
Dr. Gregory Catlett
FAQs
PUBLIC OFFERING AND LISTING
Please note that SEC Rule 144 mandates that shares purchased under Reg CF (Regulation Crowdfunding) are not eligible for immediate trading and have a 12-month required lock-up period starting from when the investment closed. Equity Stock Transfer has records of when any Reg-CF series-C investments closed.
TRANSFER AGENT
- If you have already paid and registered for Online Access to our shareholder portal, and created your username and password, please skip to step 4.
- To transfer your free trading shares to your broker, you must obtain Online Access here: https://monogram-orthopaedics.equitystock.com/pay and follow the directions. Your DRS (Direct Registration System) transfer agent fees to transfer your shares to your broker are covered when you obtain Online Access.
- After you complete the payment for Online Access, you will receive email instructions on how to register.
- Once you have registered and created your username and password, through the Online Access portal, you will be able to download your Common Stock book-entry statement along with a Welcome Letter on how to initiate the DRS process through your broker.
- Once your broker initiates the DRS process, we will be able to transfer the shares to your brokerage account.
PRIOR INVESTMENTS
GENERAL
FOR FURTHER INFORMATION
This page may include ''forward-looking statements.'' To the extent that the information presented in this presentation discusses financial projections, information, or expectations about Monogram Orthopedics Inc.’s business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plans,'' and ''proposes.'' Although Monogram Orthopedics Inc. believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in the offering statement filed with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Monogram Orthopedics Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.
The offering will be made only by means of an offering circular. An offering statement on Form 1-A relating to these securities has been filed with the U.S. Securities and Exchange Commission and has become qualified. The securities offered by Monogram are highly speculative. Investing in shares of Monogram involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue.
Monogram intends to list its securities on a national exchange and doing so entails significant ongoing corporate obligations including but not limited to disclosure, filing and notification requirements, as well compliance with applicable continued quantitative and qualitative listing standards. For additional information on Monogram, the offering and any other related topics, please review the Form 1-A offering circular that can be found at the following location EDGAR Entity Landing Page. Additional information concerning Risk Factors related to the offering, including those related to the business, government regulations, intellectual property and the offering in general, can be found in the risk factor section of the Form 1-A offering circular.
DealMaker Securities, LLC is being compensated a 4% commission from the lead Selling Agent engaged by Monogram Orthopaedics Inc. in regards to advertising of this investment. The Company has engaged Digital Offering, LLC (“Digital Offering”) to act as lead selling agent (which we sometimes refer to as the “Selling Agent”) to offer the shares of our common stock, par value $0.001 (the “Common Stock”) to prospective investors in this offering on a “best efforts” basis, which means that there is no guarantee that any minimum amount will be received by the Company in this offering. The Company will pay a cash commission of 7.00% to Digital Offering on sales of the shares of Common Stock. See “Plan of Distribution” in the Offering Circular for details of compensation payable to the Selling Agent in connection with the offering. DealMaker Securities, LLC is not affiliated with other companies mentioned herein.
*NASDAQ Ticker Reservation Tracking #ME9437IN. Our request to reserve the ticker symbol "MGRM" for Monogram Orthopaedics Inc has been approved and will be reserved until 20 September 2024.
Join the Discussion